Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF versus FAYOSIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF versus FAYOSIM.
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF vs FAYOSIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective histamine H1-receptor antagonist. It inhibits the H1 receptor, reducing histamine-mediated effects such as edema, flare, and pruritus.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
5 mg or 10 mg orally once daily; maximum 10 mg per day.
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 8.3 hours in healthy adults; prolonged to ~20 hours in renal impairment (CrCl <30 mL/min).
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% is eliminated in feces.
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Category A/B
Category C
Antihistamine
Antihistamine